Menu
PTAB Blog
Biosimilars Blog
RF 360

Results

Strategic. Calculated. Successful.

Federal Circuit denies petition for rehearing regarding invalidity of YAZ® patent

Rothwell Figg secures a path for Sandoz in YAZ® contraceptive patent matter

August 12, 2013

On Monday, August 12, 2013 the Federal Circuit denied a combined petition for panel rehearing and rehearing en banc brought by Bayer Healthcare Pharmaceuticals Inc. and Bayer Schering Pharma AG – upholding the Court's April 16, 2013 decision finding that Bayer's patent for its YAZ® contraceptive product was invalid as obvious. The Federal Circuit decision allows Sandoz and other generic manufacturers to continue manufacturing and distributing generic versions of the drug.

Rothwell Figg's Joseph A. Hynds, Steven Lieberman, and Lisa Phillips represented Sandoz in this matter.